Send to

Choose Destination
PLoS Negl Trop Dis. 2019 May 16;13(5):e0007399. doi: 10.1371/journal.pntd.0007399. eCollection 2019 May.

Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009-2017).

Author information

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain.
Tropical Medicine and International Health Unit Drassanes-Vall d'Hebron, PROSICS Barcelona, Barcelona, Spain.
Ramón y Cajal University Hospital, Madrid, Spain.
Hospital Universitario 12 de Octubre, Madrid, Spain.
Hospital Universitario Central de Asturias, Oviedo, Spain.
Hospital General Universitario de Alicante, Alicante, Spain.
Hospital Universitario Cruces, Barakaldo, Spain.
Hospital de Basurto, Bilbao, Spain.
Hospital Universitario Fundación Alcorcón, Madrid, Spain.



Imported strongyloidiasis is increasingly being diagnosed in non-endemic areas. The aim of this study was to describe the epidemiological, clinical and microbiological characteristics of patients with imported strongyloidiasis in Spain.


This is an observational retrospective study that included all patients diagnosed of strongyloidiasis registered in the +REDIVI Collaborative Network from 2009 to 2017. Demographic, epidemiological and clinical information was collected from the +REDIVI database, and extra information regarding microbiological techniques, treatment and follow-up was requested to participant centers.


Overall, 1245 cases were included. Most of them were immigrants (66.9%), and South America was the most frequent area of origin. Detection of larvae in stool samples was observed in 21.9% of the patients, and serological tests allowed making the diagnosis in the rest of the cases. Eosinophilia was present in 82.2% of cases. Treatment with ivermectin (compared with albendazole) was the most strongly associated factor to achieve the cure (OR 2.34).


Given the long latency of the infection and the risk of developing a severe presentation, screening of S. stercoralis infection should be mandatory in patients coming from or had traveling to endemic areas, especially in those with immunosuppressant conditions.

Conflict of interest statement

The authors have declared that no competing interests exist

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center